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Abstract: The search for genetic risk factors in type-II diabetes has been hindered by a failure to
consider dietary variables. Dietary nutrients impact metabolic disease risk and severity and are
essential to maintaining metabolic health. Genetic variation between individuals confers differences
in metabolism, which directly impacts response to diet. Most studies attempting to identify genetic
risk factors in disease fail to incorporate dietary components, and thus are ill-equipped to capture
the breadth of the genome’s impact on metabolism. Understanding how genetic background
interacts with nutrients holds the key to predicting and preventing metabolic diseases through
the implementation of personalized nutrition. Dysregulation of iron homeostasis is associated
with type-II diabetes, but the link between dietary iron and metabolic dysfunction is poorly defined.
High iron burden in adipose tissue induces insulin resistance, but the mechanisms underlying adipose
iron accumulation remain unknown. Hepcidin controls dietary iron absorption and distribution
in metabolic tissues, but it is unknown whether genetic variation influencing hepcidin expression
modifies susceptibility to dietary iron-induced insulin resistance. This review highlights discoveries
concerning the axis of iron homeostasis and adipose function and suggests that genetic variation
underlying dietary iron metabolism is an understudied component of metabolic disease.
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1. Introduction
Diet influences metabolism, but individuals vary in metabolic response to diet, leading to different
long-term health outcomes. The term gene-environment interaction (GEI) is applied to phenomena
where two genotypes respond differently to identical environmental inputs, and to when identical
genotypes respond differently to different environmental inputs. Put another way, genetic variation
produces observable phenotypic differences under specific conditions, e.g., diet, temperature, or age [1].
While GEI connecting dietary iron and systemic metabolism are understudied, GEI connecting
dietary iron and iron homeostasis have been observed. For example, a study examining the
effectiveness of iron supplementation in a cohort of 334 anemic infants with low hemoglobin observed
that, despite regular consumption of iron-fortified baby formula, only 34% of the infants showed
improved iron status over a 6-month period [2]. Another study examined iron status in an elderly
population (n = 1016), and found that 12.9% of individuals had clinically high levels of iron stores,
despite normal levels of iron consumption [3]. These studies suggest there is substantial variation in
iron homeostasis in human populations, and that GEI likely underlies individual response to dietary
iron. Characterizing the genetic variation and dietary conditions that underlie differences in response
to dietary iron may translate into therapeutic strategies for individuals with iron-associated metabolic
disease. This review focuses on the role of iron in metabolic homeostasis and disease, and calls for
researchers to incorporate dietary iron components when searching for genetic risk factors.
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2. Diet and Diabetes: A Need for Dietary Perspective
Prevalence of diabetes mellitus type II (T2D) has risen since the 1960’s, while prevention and treatment
remain an enormous challenge. There are a variety of “one-size-fits-all” treatments available, including
exercise- and dietary-based interventions, prescription of Metformin, and weight loss surgery if T2D is
accompanied by obesity. Unfortunately, even with strict adherence to these therapies, most patients are at
risk of developing cardiovascular disease [4]. Appropriate biomarkers are needed to assess individual risk
and prescribe appropriate precision therapeutic strategies. Genome-wide association studies (GWAS) have
identified 8–30 loci associated with insulin resistance and T2D, but these loci only explain ~10% of the total
heritability of the disease [5–10]. This is known as the problem of “missing heritability”, and can, in part,
be explained by a failure to account for environmental influences.
Few studies have attempted to include environmental factors into GWAS analysis, uncovering
GEI. Examples include polymorphisms in peroxisome proliferator-activated receptor gamma (PPARG)
that increase fasting insulin levels only when high levels of polyunsaturated fats are consumed,
and polymorphisms in zinc transporter SLC30A8, which are associated with elevated fasting glucose
levels in a zinc-deficient diet [11,12]. Unfortunately, adding environmental variables to GWAS reduces
the power to detect association and depends on participants to report dietary habits. Thus, candidate
gene approaches have been adopted to examine the genetic underpinnings of T2D. Inbred mouse
strains provide a valuable resource because of their high genetic and physiologic homology to humans
and the ease of environmental manipulation. For example, a quantitative trait locus (QTL) associated
with variation in triglycerides identified HPX (Hemopexin) as a top candidate gene in an F16 advanced
intercross between the LG/J and SM/J strains of mice [13]. Hemopexin sequesters plasma heme,
preventing oxidative stress and heme-bound iron loss. Functional follow-up of this candidate found
that it impacts adipocyte differentiation, shows altered expression in obese adipose in both mice and
humans, and is correlated with triglycerides [13]. Studies that leverage results generated by multiple
experimental procedures, e.g., forward genetics screens, human and mouse gene expression analysis,
and molecular functional studies, will shed light on the underlying mechanisms behind GWAS loci
and highlight what genes may be critical under specific environmental conditions [14].
3. Dietary Iron: Too Much of A Good Thing?
Dietary iron is absorbed by duodenal enterocytes that express ferroportin, allowing iron to pass
from the lumen of the gut into the bloodstream [15]. Plasma iron is bound by circulating transferrin,
the primary iron transport molecule, and cells take in transferrin via transferrin receptors [16].
Upon entrance into the cell, iron is stored by the iron-chelating protein ferritin, which forms protein
aggregates and prevents iron from engaging in redox reactions [17]. Iron-bound ferritin also circulates
in the bloodstream, serving as a convenient metric for assessing total body iron stores. Iron storing
tissues can release iron back into the bloodstream by expressing ferroportin [18].
Iron deficiency is the most common nutritional deficiency in the world, affecting about two
billion people [19]. Iron deficiency is associated with metabolic complications including cardiovascular
disease (CVD) and T2D, mainly through the development of anemia, where insufficient iron availability
decreases red blood cell production [20,21]. Western countries have low levels of iron deficiency due
to iron fortification of commonly consumed grains including wheat flour, corn meal, and rice [22].
Consumption of dietary iron has increased dramatically in the last 30 years, trending with the rise of
T2D [23]. Patients with T2D have significantly elevated serum ferritin levels, and multiple studies
associate dietary iron intake and diabetes risk [24–27]. Longitudinal analysis of iron-overloaded
individuals found that patients in the highest quartile of serum ferritin levels have 3.5-fold greater risk
of developing T2D over a 6-year follow-up period [28]. High serum ferritin is individually associated
with increased BMI, hypertension, dyslipidemia, and reduced insulin sensitivity [29]. A limited
number of studies have examined the reduction of serum ferritin by phlebotomy in patients with T2D
with promising results, improving insulin sensitivity, insulin secretion and decreasing basal glucose
levels [30]. Interestingly, ferritin is elevated during inflammation and infection, which complicates
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interpreting changes in ferritin levels in individuals with metabolic disease, who often have chronic
inflammation [31]. Iron has been investigated as a risk factor in CVD, independent of T2D; however,
results remain inconclusive [32]. Both iron deficiency and iron overload are implicated in metabolic
disease, which underscores the importance of maintaining iron levels within a narrow physiological
range. These studies connect iron stores and diabetes, but the genetic and physiologic mechanisms
through which dietary iron contributes to T2D etiology are incompletely understood.
While all tissues require iron, the liver is the primary iron sensing organ. When the liver
accumulates high levels of iron, the HAMP gene (hepcidin) is upregulated and secreted into the
blood stream. Hepcidin binds and inhibits ferroportin in iron-storing tissues including the liver,
adipose tissue, the spleen, macrophages, and duodenal enterocytes [33]. In enterocytes, inhibition of
ferroportin by hepcidin reduces absorption of dietary iron into the blood stream by trapping it within
the enterocyte, lowering circulating transferrin levels. Likewise, hepcidin inhibition of ferroportin in
liver and adipose tissue prevents the export of iron in these cells, which increases iron retention within
the tissue, and further decreases circulating transferrin availability. It follows that genetic variation in
this pathway can lead to disruption of iron homeostasis.
Early evidence that dysregulation of iron homeostasis contributes to metabolic disease comes
from the genetic iron-overload disorder hereditary hemochromatosis (HH). HH is characterized by
loss of function mutations in the hepcidin pathway, leading to the inability to inhibit iron uptake and
causing systemic iron overload. HH individuals have a 60% chance of developing T2D in their lifetime,
compared to 35% in the general population [34]. Regular phlebotomy temporarily reduces circulating
iron burden and blood glucose levels in HH subjects with T2D [35]. Mouse models of HH reveal that
chronic iron overload decreases insulin secretion capacity due to high levels of oxidative stress [36].
While these studies connect iron stores and diabetes, the genetic and physiologic mechanisms through
which dietary iron contributes to T2D etiology in non-HH individuals are incompletely understood.
A small number of studies have investigated the metabolic consequences of a high iron diet in mice,
finding association with altered glucose and insulin homeostasis. C57BL/6J mice fed a high iron diet
for 16 weeks had higher basal glucose levels, decreased insulin signaling assessed by phospho-Akt/Akt
ratio, and impaired insulin tolerance assessed via an insulin tolerance test [37]. Another study found
that C57BL/6J mice fed a combination high-iron/high-fat diet for seven weeks experienced greater
dysregulation of insulin signaling than high-fat-fed mice alone, in part by increasing hepatic iron load,
altering hepatic mitochondrial function, and increasing Interleukin-6 (IL6) inflammatory signaling.
These results suggest dietary iron and fat work synergistically to alter systemic glucose metabolism [38].
Additionally, dietary iron restriction and iron chelation protected genetically obese ob/ob mice from
insulin resistance and β-cell failure [39]. These studies indicate that iron overload can produce
diabetic-like phenotypes by interfering with insulin sensitivity and hepatic gluconeogenesis, and by
decreasing pancreatic β-cell insulin production. These studies are consistent with observations of
dysregulated iron homeostasis in human subjects with T2D, and provide opportunities to study these
mechanisms in depth. However, these studies do not incorporate multiple genetic backgrounds, so the
breadth of the effect of dietary iron on metabolism may not be fully characterized.
4. Adipose Tissue: At the Intersection of Iron and Insulin Sensitivity
Adipose tissue is a dynamic endocrine organ that contributes to systemic glucose and insulin
homeostasis by producing signaling molecules including adipokines in response to changes in energy
and nutrient availability [40]. These adipose-specific functions influence systemic insulin sensitivity
by altering the behavior of other metabolic tissues including skeletal muscle and liver. Increased iron
burden in adipocytes negatively impacts adipokine signaling, implicating iron sequestration in adipose
as a driver of insulin resistance [41,42].
Adipocytes produce the adipokine adiponectin in response to decreased energy availability,
which promotes insulin sensitivity by stimulating translocation of glucose transporter GLUT4 to
the cell membrane of skeletal muscle and liver [40]. Serum ferritin is negatively correlated with
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serum adiponectin in T2D patients [43], and phlebotomy increases adiponectin levels and improves
insulin sensitivity, potentially through reduction of iron load. In vitro addition of physiologically high
levels of iron to 3T3-L1 cells decreases adiponectin secretion through increased Foxo1 expression,
a transcription factor involved in adipocyte functions including adipogenesis, gluconeogenesis,
and insulin signaling [34]. These studies reveal iron can directly impact adiponectin levels and
alter systemic insulin sensitivity, and highlight key candidate genes that connect iron to adipose
biology. Variants in these genes may contribute to variation in their function in response to iron stores.
Leptin is another adipokine that directly influences insulin sensitivity by stimulating expression
of Glut4 in target tissues. Leptin also induces lipolysis and decreases lipogenesis in muscle and
liver tissue which is critical to prevent lipotoxic accumulation of triglycerides, which is linked to
insulin resistance [44]. C57BL/6J mice fed a high iron diet have decreased leptin expression in
adipose tissue and lower circulating leptin levels. In vitro, treatment of 3T3-L1 adipocytes with ferric
ammonium citrate (an iron source) decreased Lep expression by 48% and secreted leptin by 36% [45].
Further, leptin expression and protein level could be rescued by addition of deferoxamine, an iron
chelator. Examination of the leptin promoter identified CREB binding, a responder to high cAMP levels,
as an inhibitory mechanism in response to high iron conditions. In sum, high iron load in adipose tissue
decreases leptin expression and protein levels, which in turn decreases systemic insulin sensitivity.
In contrast to adiponectin and leptin, the adipokine resistin is associated with decreased insulin
sensitivity and negative health outcomes [46]. Resistin stimulates expression of suppressor of cytokine
signaling 3 (Socs3) in mouse muscle tissue, which inhibits insulin receptor phosphorylation and
activation of the insulin pathway. C57BL/6J mice fed a high iron diet show a 3.3-fold increase in serum
resistin levels, and a subsequent 2.1-fold increase in adipose Socs3 expression [37]. The mechanism
through which iron induces resistin expression is not well characterized, but may reveal novel
mechanisms in the relationship between iron and adipose health. Investigating how genetic variants in
these key adipokines, adiponectin, leptin, and resistin, interact with dietary iron will open new avenues
of research into adipose biology and iron’s effects on systemic metabolism. Further, investigating the
cause of iron accumulation in adipose tissue promises to reveal novel risk factors associated with
iron-induced insulin resistance.
5. Hepcidin: A Potential Link between Dietary Iron, Adipose Tissue, and Insulin Resistance
Hepcidin is a small peptide secreted by the liver that plays a regulatory role in iron metabolism.
It binds and inhibits the iron exporter ferroportin, triggering endocytosis and degradation [33].
Loss of function mutations in the hepcidin pathway were independently identified as the cause
of hemochromatosis (HH), a disease characterized by systemic iron-overload [47]. Proper hepcidin
expression is integral to maintaining intracellular and plasma iron concentrations, making it an
attractive candidate for investigating gene X dietary iron effects on metabolism.
The role of hepcidin in non-HH cases of T2D has been scantly investigated, with conflicting
results. A cross-sectional analysis of 239 non-diabetic and 65 diabetic individuals revealed that
diabetics had significantly lower circulating hepcidin levels, independent of inflammation status [48].
This study complements the observed high rate of diabetes in HH patients, who have reduced hepcidin
expression. Other studies found that T2D patients have significantly higher serum hepcidin levels
compared to healthy individuals, and serum hepcidin levels correlate with serum glucose levels [49,50].
However, a third study found no significant association between hepcidin and the onset of T2D [51].
While these findings seem contradictory, it may be explained by comparing systemic vs adipose-specific
iron overload. Individuals with low hepcidin expression, including HH patients, are unable to inhibit
enterocyte ferroportin, leading to continuous dietary iron absorption. This would result in systemic
iron overload, where all tissues, including adipose, have a high iron burden. While adipose tissue
can export iron via ferroportin, toxic accumulation of iron would occur due to the high concentration
of circulating iron. Conversely, T2D individuals with high hepcidin expression have low ferroportin
activity on enterocytes and adipose. In these patients, dietary iron absorption is low, but any circulating
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iron is sequestered in adipose tissue without means to be exported. This leads to iron-overload of
adipose tissue with low iron availability for other tissues, causing the so-called “anemia of chronic
disease”. Through systemic or adipose-specific mechanisms, both low and high levels of hepcidin
expression can induce iron-overload in adipose tissue. These contradictory findings reflect the complex
regulatory mechanisms that govern hepcidin expression.
Hepcidin is regulated through two pathways, iron-sensing and inflammation-sensing, that converge
on the 650 base pair proximal promoter region (Figure 1). The iron-sensing pathway is activated by
circulating transferrin (TF), which binds to a transferrin receptor (TFR). This complex interacts with
cofactors including HFE and hemojuvulin (HJV), which in turn sensitize BMP-receptor (BMPR) to BMP.
Activation of BMPR activates the SMAD signaling pathway, resulting in SMAD4 binding at BMP response
elements, increasing HAMP transcription [52]. Transmembrane Serine Protease 6 (TMPRSS6) inhibits HJV
action, reducing BMP6R sensitivity. Loss of function mutations in HFE, HJV, TFR, and BMP receptor cause
HH, while variants in TMPRSS6 are associated with reduced risk for T2D [53,54].
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increases hepcidin expression. C/EBPα is a highly expressed hepatocyte transcription factor, and is a
necessary cofactor for IL-6 and transferrin stimulated activation of hepcidin [55]. Furthermore, hepcidin
expression is directly regulated by insulin through STAT3 promoter binding and fasting insulin level
is negatively correlated with HAMP mRNA expression in diabetic humans [56,57]. Taken together,
the relationship between hepcidin and insulin sensitivity may be bidirectional, and is likely influenced
by genetic variation in the hepcidin activation pathways.
Individuals vary greatly in total iron deposition and genetic variation in the hepcidin pro oter
is directly associated ith iron status. study exa ining the effects of pro oter haplotypes on
hepcidin gene expression in eight inbred strains of ice found several pro oter poly orphis s in
transcription factor binding sites that influence a p expression up to 3-fold [58]. In hu ans, three
S Ps in the 5′ pro oter region of P are associated ith severe iron overload including binding
sites for S and ST T3 (Figure 1) [59–61]. It is likely ore regulatory variants influence hepcidin
expression, and these ay be context dependent. To date, no study has exa ined the role of hepcidin
promoter polymorphisms in response to dietary iron. Polymorphisms in the hepcidin promoter can
influence hepcidin expression and iron-loading in metabolic tissue, yet it remains unknown if hepcidin
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expression per se is a risk factor for T2D. Furthermore, it is unknown if, or to what degree, dietary
iron facilitates this risk. Given the role of iron in the development of T2D, it is plausible that hepcidin
expression may contribute to iron loading in adipose tissue leading to decreased insulin sensitivity and
metabolic dysfunction. Identification and molecular characterization of genetic variants influencing
hepcidin expression will provide new insights into the metabolic consequences of dietary iron in T2D.
6. Concluding Remarks
Prevention of diabetes remains a major challenge because of the polygenic nature of metabolic
traits and the ability of diet to modify genetic risk. Dietary iron is an understudied component of
this equation, despite the increase in iron fortification that correlates with increased T2D prevalence.
Dysregulation of iron homeostasis is heavily implicated in metabolic disease, and high levels of
dietary iron have been shown to induce insulin resistance through dysregulation of adipose tissue.
Metabolic homeostasis is heavily influenced by genetic background, but the genetic architecture
underlying iron’s influence on adipose tissue has not been investigated. Hepcidin is a promising
candidate linking genetic variation, dietary iron, and adipose tissue function. These lines of evidence
converge on a central question: how does genetic background modify the relationship between
dietary iron and metabolic disease? Future efforts to uncover genetic risk factors for diabetes should
consider including a dietary iron component. Dietary intervention studies in mice should include
multiple genetic backgrounds to better characterize the range of dietary iron’s influence on metabolism.
Combining these approaches will identify iron-related risk factors on a demographic level, and provide
mechanistic insight into how genetic markers translate into metabolic response to diet.
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